D
David W. Hogg
Researcher at University of Toronto
Publications - 121
Citations - 29207
David W. Hogg is an academic researcher from University of Toronto. The author has contributed to research in topics: Melanoma & Germline mutation. The author has an hindex of 34, co-authored 113 publications receiving 25771 citations. Previous affiliations of David W. Hogg include University Health Network & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Studies of Differentially-Expressed Genes in Human Endometrial Cancer of Various Differentiated Grades
Bin Cai,David W. Hogg,Guangzhong Lu,Ling Liu,Xiaowei Xi,Wei Xu,Huifang Lu,Yongbin Yang,Xiao-Ping Wan +8 more
TL;DR: Genes related to the differentiation of endometrial cancer can be identified by using gene chips to analyze the expression profiles ofendometrial cancers at various differentiated grades; HCA of the gene expression profiles can be helpful for distinguishing high-risk endometrian cancers before surgery.
Book ChapterDOI
Corticotropin-Releasing Hormone Family of Peptides
TL;DR: Dysfunction of the CRH signaling system is implicated in affective and neurological disorders and elucidation of the physiological role played by CRH will be critical for development of therapeutics aimed at treating these conditions.
Posted ContentDOI
Regulation of skeletal muscle metabolism and contraction performance via teneurin-latrophilin action
Andrea L. Reid,David W. Hogg,Thomas L. Dodsworth,Yani Chen,Ross M. Reid,Mei Xu,Mia Husić,Peggy R. Biga,Andrew Slee,Leslie T. Buck,Dalia Barsyte-Lovejoy,Marius Locke,David A. Lovejoy +12 more
TL;DR: In this paper, the teneurin/TCAP-LPHN system is presented as a novel mechanism likely to regulate the energy requirements and performance of skeletal muscle, which increases energy metabolism and enhances skeletal muscle function via increases in type-1 oxidative fiber formation and reduce the fatigue response.
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
Paul B. Chapman,Axel Hauschild,C. Robert,James Larkin,J.B.A.G. Haanen,A. Ribas,David W. Hogg,Steven J. O'Day,P.A. Ascierto,A. Testori,Paul Lorigan,R. Dummer,J. A. Sosman,Claus Garbe,R. J. Lee,K. B. Nolop,B. Nelson,Jeannie Hou,Keith T. Flaherty,Grant A. McArthur +19 more
Journal ArticleDOI
Bm-16increased acute radiation effect (are) with ipilumumab and radiosurgery in patients with melanoma brain metastases.
Leila Khoja,Leila Khoja,Goldie Kurtz,Goldie Kurtz,Gelareh Zadeh,Gelareh Zadeh,Normand Laperriere,Normand Laperriere,Cynthia Ménard,Cynthia Ménard,Barbara-Ann Millar,Barbara-Ann Millar,Mark Bernstein,Mark Bernstein,Paul Kongkham,Paul Kongkham,Anthony M. Joshua,Anthony M. Joshua,David W. Hogg,David W. Hogg,Marcus O. Butler,Marcus O. Butler,Caroline Chung,Caroline Chung +23 more
TL;DR: Following SRS for brain mets and Ipi, ARE was seen in 23% of patients within 4 months of starting Ipi treatment, greater than the commonly reported 10% risk of ARE after SRS alone for brain metastasis.